COGZF:OTO-Cogstate Ltd Ord (USD)

COMMON STOCK | Health Information Services | OTC Pink

Last Closing

USD 0.83

Change

0.00 (0.00)%

Market Cap

USD 0.09B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cogstate Ltd is engaged in sale of computerised tests of cognition and associated services including scientific consultancy, project management, data management, statistical analysis and reporting.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap
PMCUF Pro Medicus Limited

N/A

USD 8.70B
MTHRF M3 Inc

N/A

USD 7.77B
MTHRY M3 Inc

N/A

USD 7.06B
PANHF Ping An Healthcare and Technol..

N/A

USD 1.64B
CRWRF Craneware plc

N/A

USD 1.09B
SMSZF SMS Co. Ltd

N/A

USD 1.09B
SUSRF Surgical Science Sweden AB (pu..

N/A

USD 0.71B
RSLBF RaySearch Laboratories AB (pub..

N/A

USD 0.44B
VHIBF Vitalhub Corp

N/A

USD 0.27B
KSIOF kneat.com inc.

N/A

USD 0.27B

ETFs Containing COGZF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health Information Services) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.63% 44% F 26% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.63% 42% F 25% F
Trailing 12 Months  
Capital Gain -17.82% 62% D 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.82% 60% D- 40% F
Trailing 5 Years  
Capital Gain 492.86% 95% A 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 492.86% 95% A 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 76.77% 85% B 81% B-
Dividend Return 76.77% 85% B 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 107.47% 41% F 32% F
Risk Adjusted Return 71.43% 98% N/A 95% A
Market Capitalization 0.09B 89% A- 59% D-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector